Inhibikase Halts Parkinson's Drug Development to Focus on PAH
Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...
Hosted on MSN15h
Researchers Apply Advanced AI Genetics Models to Study Parkinson's Disease
Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...
AI model identifies potential risk genes for Parkinson's disease
Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...
The Engineer21h
AI models spot potential risk genes for Parkinson’s disease
Advanced artificial intelligence genetics models have been successfully applied to Parkinson’s disease at CCGC.